Paul Herzich
Chief Tech/Sci/R&D Officer en SOLID BIOSCIENCES INC. .
Fortuna: 80 213 $ al 31/03/2024
Perfil
Paul Herzich is currently the Chief Technology Officer at Solid Biosciences, Inc. Prior to this, he held positions as Director-CGMP & Senior Manager at Bamboo Therapeutics, Inc., Senior Director-Manufacturing at LogicBio Therapeutics, Inc., Vice President-CMC at BridgeBio Pharma, Inc., and Chief Technology Officer at Aavantibio, Inc. He also served as Head-TD Manufacturing at Csl Seqirus from 2007 to 2015.
Dr. Herzich received an undergraduate degree from Rutgers State University of New Jersey and an MBA from Poole College of Management.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
SOLID BIOSCIENCES INC.
0.02% | 13/02/2024 | 6 022 ( 0.02% ) | 80 213 $ | 31/03/2024 |
Cargos activos de Paul Herzich
| Empresas | Cargo | Inicio |
|---|---|---|
| SOLID BIOSCIENCES INC. | Chief Tech/Sci/R&D Officer | 01/12/2022 |
Antiguos cargos conocidos de Paul Herzich.
| Empresas | Cargo | Fin |
|---|---|---|
Aavantibio, Inc.
 Aavantibio, Inc. BiotechnologyHealth Technology Aavantibio, Inc. engages in developing gene therapies. The company was founded by Barry Byrne and Manuela Corti and is headquartered in Gainesville, FL. | Chief Tech/Sci/R&D Officer | 01/12/2022 |
| BRIDGEBIO PHARMA, INC. | Corporate Officer/Principal | 01/04/2021 |
| LOGICBIO THERAPEUTICS, INC. | Corporate Officer/Principal | 01/07/2019 |
Bamboo Therapeutics, Inc.
 Bamboo Therapeutics, Inc. BiotechnologyHealth Technology Bamboo Therapeutics, Inc. develops gene therapy products for central nervous system and neuromuscular diseases. Its therapeutic platform is based on the use of Adeno-associated virus as a gene therapy vehicle. The company’s proprietary technologies include chimeric vectors, self-complementary vectors, and dual glycan receptor. It focuses on the treatment of Duchenne muscular dystrophy, giant axonal neuropathy, Friedreich ataxia, and Canavan disease. Bamboo Therapeutics was founded by Richard Jude Samulski, Sheila A. Mikhail, Josh Grieger, Xiao Xiao, and Paola Leone in December 2014 and is headquartered in Chapel Hill, NC. | Corporate Officer/Principal | 01/01/2018 |
| Csl Seqirus | Corporate Officer/Principal | 01/07/2015 |
Formación de Paul Herzich.
| Rutgers State University of New Jersey | Undergraduate Degree |
| Poole College of Management | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| SOLID BIOSCIENCES INC. | Health Technology |
| BRIDGEBIO PHARMA, INC. | Health Technology |
| Empresas privadas | 4 |
|---|---|
Bamboo Therapeutics, Inc.
Bamboo Therapeutics, Inc. BiotechnologyHealth Technology Bamboo Therapeutics, Inc. develops gene therapy products for central nervous system and neuromuscular diseases. Its therapeutic platform is based on the use of Adeno-associated virus as a gene therapy vehicle. The company’s proprietary technologies include chimeric vectors, self-complementary vectors, and dual glycan receptor. It focuses on the treatment of Duchenne muscular dystrophy, giant axonal neuropathy, Friedreich ataxia, and Canavan disease. Bamboo Therapeutics was founded by Richard Jude Samulski, Sheila A. Mikhail, Josh Grieger, Xiao Xiao, and Paola Leone in December 2014 and is headquartered in Chapel Hill, NC. | Health Technology |
LogicBio Therapeutics, Inc.
 LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
Aavantibio, Inc.
Aavantibio, Inc. BiotechnologyHealth Technology Aavantibio, Inc. engages in developing gene therapies. The company was founded by Barry Byrne and Manuela Corti and is headquartered in Gainesville, FL. | Health Technology |
| Csl Seqirus |
- Bolsa de valores
- Insiders
- Paul Herzich
